# Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma

> **NCT03168594** · PHASE2 · TERMINATED · sponsor: **Peking University** · enrollment: 66 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** irinotecan cisplatin
- **DRUG:** Etoposide cisplatin

## Key facts

- **NCT ID:** NCT03168594
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-29
- **Primary completion:** 2019-02-20
- **Final completion:** 2019-09-20
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** The enrollment was terminated early because the premature analysis found similar response in the two arms.
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168594, "Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03168594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*